title: Sarcoidosis induced by interferon-α in melanoma patients: incidence, clinical manifestations, and management strategies.
abstract: Treatment with interferon-α has been recommended for patients with melanoma in case of micrometastases, or high risk melanoma, for example, ulcerated melanoma. Furthermore, regular dermatologic examination and regular imaging to detect recurrence or progression of disease is part of the management of melanoma patients. Sarcoidosis has been described as an adverse effect of treatment with interferon-α. Especially in hepatitis C patients, there is a series of case reports on sarcoidosis induced by interferon treatment whereas in melanoma this has rarely been reported. In a retrospective study, all melanoma patients treated with interferon-α at our hospital between 2007 and 2009 were screened for occurrence of sarcoidosis. Three of 16 melanoma patients treated with interferon-α (19%) presented with sarcoidosis. All 3 patients showed lesions with higher uptake in the positron emission tomography-computed tomography scan leading to the differential diagnosis of melanoma metastases or inflammation. Skin lesions were present in 1 patient. Diagnosis was confirmed by histologic assessment of lesions showing epithelioid granuloma-negative on Ziehl Neelson. Additional work-up included blood and urinalysis, electrocardiography, and ophthalmologic examination. Cessation of interferon-α led to regression of granulomas. Sarcoidosis induced by interferon-α in melanoma patients could be more common than previously thought. This is an important complication to be aware of as it can be mistaken for metastatic spread of melanoma and thus lead to incorrect therapy.
authors.affiliation: Department of Dermatology and Allergies, Cantonal Hospital St Gallen, Switzerland. lucie.heinzerling@kssg.ch
authors.forename: Lucie M
authors.initials: LM
authors.lastname: Heinzerling
authors.forename: Mark D
authors.initials: MD
authors.lastname: Anliker
authors.forename: Joachim
authors.initials: J
authors.lastname: Müller
authors.forename: Marc
authors.initials: M
authors.lastname: Schlaeppi
authors.forename: Roger
authors.initials: R
authors.lastname: von Moos
mesh_terms: D003937:Diagnosis, Differential; D018450:Disease Progression; D006099:Granuloma; D006526:Hepatitis C / Q000453:epidemiology; D006801:Humans; D007167:Immunotherapy; D015994:Incidence; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012189:Retrospective Studies; D012507:Sarcoidosis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D028761:Withholding Treatment
chemical_list: D016898:Interferon-alpha